What: Oncothyreon is down 30% at 1:30 p.m. EST after announcing updated data from its ongoing trials testing ONT-380 in patients with breast cancer yesterday. So what: From the stock move, you'd think ...
A barrage of post-shutdown data this week has left economists with more questions than answers about the state of the U.S. economy. Unemployment rose to a four-year high in November, inflation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results